NCT02916771: Phase 2: Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in SMM

NCT02916771: Phase 2: Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

This research study is evaluating a new drug called "ixazomib" as a possible treatment for Smoldering Multiple Myeloma.

Sponsor

Dana-Farber Cancer Institute

Collaborators

Celgene

Takeda

---

ClinicalTrials.gov Identifier: NCT02916771

Official Title: Phase II Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

First Posted : September 27, 2016

Click here for details on ClinicalTrials.gov

---

Drug: Ixazomib

Drug: Lenalidomide

Drug: Dexamethasone

---

Location

United States, Massachusetts